Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 15.42 USD 3.77% Market Closed
Market Cap: 1.3B USD

Wall Street
Price Targets

VRDN Price Targets Summary
Viridian Therapeutics Inc

Wall Street analysts forecast VRDN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRDN is 40.16 USD with a low forecast of 19.19 USD and a high forecast of 64.05 USD.

Lowest
Price Target
19.19 USD
24% Upside
Average
Price Target
40.16 USD
160% Upside
Highest
Price Target
64.05 USD
315% Upside
Viridian Therapeutics Inc Competitors:
Price Targets
6855
Ascentage Pharma Group International
7% Downside
OSE
OSE Immunotherapeutics SA
207% Upside
RXRX
Recursion Pharmaceuticals Inc
33% Upside
ALDX
Aldeyra Therapeutics Inc
215% Upside
ARGX
argenx SE
36% Upside
4882
Perseus Proteomics Inc
94% Upside
397030
AprilBio Co Ltd
97% Upside
TWST
Twist Bioscience Corp
45% Upside

Revenue
Forecast

Revenue Estimate
Viridian Therapeutics Inc

For the last 8 years the compound annual growth rate for Viridian Therapeutics Inc's revenue is -26%. The projected CAGR for the next 3 years is 836%.

-26%
Past Growth
836%
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Viridian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Viridian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-70%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VRDN's stock price target?
Price Target
40.16 USD

According to Wall Street analysts, the average 1-year price target for VRDN is 40.16 USD with a low forecast of 19.19 USD and a high forecast of 64.05 USD.

What is Viridian Therapeutics Inc's Revenue forecast?
Projected CAGR
836%

For the last 8 years the compound annual growth rate for Viridian Therapeutics Inc's revenue is -26%. The projected CAGR for the next 3 years is 836%.

Back to Top